Amgen's Scale and Free Cash Flow Spark Debate Over Value

Amgen has experienced significant growth over the past six months, outperforming the S&P 500 by 5.7%. The company's stock price has risen to $441.95, representing a 16.5% gain. This upward trend can be attributed in part to its solid quarterly results.

The biotechnology company benefits from economies of scale, which gives it negotiating leverage with suppliers and allows for greater brand recognition and investment firepower. With $38.1 billion in revenue over the past 12 months, Amgen has significant negotiating power in a heavily regulated industry.

Amgen's excellent free cash flow margin also enables it to reinvest, return capital to investors, and stay ahead of competition while maintaining an ample cushion. The company's average free cash flow margin was among the best in the healthcare sector over the last five years at 28.2%. However, its return on invested capital (ROIC) has decreased significantly over the last few years.

Only time will tell if Amgen's new investments can bear fruit and potentially reverse this trend. The company trades at 18.9 times forward P/E, which may be a concern for some investors.